Announcements Trials
Browse Landscape

Phase

Phase NA 61Phase 2 11Phase 3 6Phase 4 4Phase 1 4Phase 1/2 3Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 91Neoplasms 75Prostatic Neoplasms 54Carcinoma, Hepatocellular 53Colorectal Neoplasms 49Leukemia, Myeloid, Acute 41Stomach Neoplasms 36Carcinoma, Non-Small-Cell Lung 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Neoplasm Metastasis 29Pancreatic Neoplasms 27Lung Neoplasms 26Rectal Neoplasms 23Multiple Myeloma 21Hematologic Neoplasms 21Head and Neck Neoplasms 20Colonic Neoplasms 20Recurrence 19Lymphoma 19Leukemia 19Polycystic Ovary Syndrome 16Liver Neoplasms 14Esophageal Neoplasms 14Brain Neoplasms 13Myelodysplastic Syndromes 12Melanoma 12Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Motor Activity 11Fatigue 11

Interventions

Carnitine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Heart Failure × Clear all
NCT00247975 2022-08-16

Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Ottawa Heart Institute Research Corporation

Phase 2/3 Terminated
36 enrolled
Breast

Breast Neoplasms, Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡